On November 19, 2026 Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) ("Amplia" or the "Company") reported that it has received ethics approval for its ACCENT-Mini trial in metastatic pancreatic cancer. Ethics approval is a key milestone in launching a clinical study, allowing patient recruitment to begin as soon as site approvals are finalised.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ACCENT-Mini will evaluate daily dosed narmafotinib in combination with the chemotherapies gemcitabine and Abraxane. The trial builds on the encouraging results of the ACCENT trial, in which intermittently dosed narmafotinib plus chemotherapy improved outcomes across all measures of activity compared to chemotherapy alone. Notably, ACCENT delivered a complete response rate of 7.8% and a median overall survival of 11.1 months, with no significant changes to the tolerability profile of chemotherapy alone.
Three (3) clinical trial sites in Australia have been selected for ACCENT-Mini, and trial start-up activities at all sites are well advanced.
Safety and pharmacokinetic data from ACCENT-Mini are expected in late Q1/early Q2 2027. These data will form part of Amplia’s protocol submission to the FDA for the registrational study of narmafotinib in pancreatic cancer.
The ACCENT-Mini trial is an important step in Amplia’s strategy to build the clinical evidence for narmafotinib as a partner drug in combination treatments for hard-to-treat cancers, including pancreatic cancer. A major challenge in these cancers is that tumours often become resistant to both existing treatments and newer targeted medicines, such as KRAS inhibitors, limiting how effectively they work. Amplia believes narmafotinib has the potential to help overcome this challenge and make these treatments more effective for patients.
Amplia Therapeutics CEO and MD Dr Chris Burns commented: "We are delighted to have received ethics approval for this important study of narmafotinib in metastatic pancreatic cancer, a devastating disease where patients have limited treatment options. Based on our preclinical studies and clinical experience to date, we believe that combining chemotherapy with daily-dosed narmafotinib has the potential to deliver improved outcomes, and we look forward to exploring this in ACCENT-Mini."
This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.
(Press release, Amplia Therapeutics, NOV 19, 2026, View Source [SID1234675025])